Marco Arrese

TL;DR: A panel of international experts from 22 countries propose a new definition of metabolic-dysfunction-associated fatty liver disease that is both comprehensive yet simple for the diagnosis of MAFLD and is independent of other liver diseases.

TL;DR: The authors in this article examined the state of NAFLD among different regions and understand the global trajectory of this disease, an international group of experts came together during the 2017 American Association for the Study of Liver Diseases Global NASFLD Forum and provided a summary of this forum and an assessment of the current state of NASH worldwide.

TL;DR: Down-regulation of Mrp2 expression may explain impaired biliary excretion of amphiphilic anionic conjugates in these models of cholestasis.

TL;DR: The authors comprehensively discuss the key factors that trigger hepatic inflammation, as well as the pathways involved in inflammation resolution, which help to design targeted therapies able to halt or reverse disease progression in NASH.

TL;DR: Current available data on the relationships of bile acids to NAFLD and the potential for therapeutically targeting bile‐acid‐related pathways to address this growing world‐wide disease are summarized.